Conclusions: These findings hinge on the assumption of longer-term survival but suggest that the use of CAR-T therapy is approaching standard ICER thresholds.

Conclusions: While the Shiny method has confirmed its validity in reconstructing individual patient data, our indirect comparisons have offered some original clues to interpret the results of OS published in these studies.

Conclusions: Several novel drugs have improved first-line and second-line treatment of DLBCL in clinical practice. De-escalation of low-risk patients reduces acute and late side-effects. New treatment concepts such as CAR-T cells and bispecific antibodies will further improve the outcome of high-risk patients.

Conclusions: This comprehensive examination of BMI and survival in newly diagnosed MM patients suggests that underweight and severe obesity are associated with worse survival. Future studies of weight trajectories and body composition may help clarify these observations. Additionally, clinical research to understand if patients with extreme BMI...

Conclusions: In this comprehensive review, the authors describe the development of CAR T-cell therapies in myeloma, the outcomes of notable clinical trials, the toxicities and limitations of CAR T-cell therapies, and the strategies to overcome therapeutic challenges of CAR T cells in the hope of achieving a cure for multiple myeloma.